Physician profile
David D Hult
NPI 1457322281
$1,170.47
in general payments reported to CMS, 2019-2025
24 companies · $30.17 in 2025
The $30.17 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $254 · 2021: $422 · 2022: $66.86 · 2023: $139 · 2024: $97.37 · 2025: $30.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.74 | 2021-2023 | |
| Amgen INC. | $121.53 | 2019-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $113.05 | 2019-2024 | |
| Novo Nordisk INC | $102.79 | 2019-2025 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $60.82 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $48.47 | 2020-2022 | |
| Allergan, INC. | $43.63 | 2020 | |
| Boston Scientific Corporation | $39.30 | 2020-2023 | Watchman Flx |
| Antares Pharma, INC. | $38.33 | 2020 | |
| Merck Sharp & Dohme LLC | $36.27 | 2020-2021 | |
| Pfizer INC. | $32.32 | 2021 | |
| Adlon Therapeutics L.P. | $31.85 | 2020 | |
| Jazz Pharmaceuticals INC. | $28.96 | 2019 | |
| Lilly USA, LLC | $27.16 | 2021 | |
| Exact Sciences Corporation | $22.31 | 2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $18.22 | 2019 | |
| Organon LLC | $17.52 | 2024 | |
| Medicure Pharma INC. | $17.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.38 | 2021 | |
| Mylan Specialty L.P. | $15.17 | 2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $13.79 | 2019 | |
| Dexcom, INC. | $13.57 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.41 | 2021 | |
| Genentech USA, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hult listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.